CYP3A5多形态对儿科喘结果的影响
Flory L Nkoy1, Bryan L Stone1, Cassandra E Deering-Rice2
1Department of Pediatrics, University of Utah School of Medicine, 100 N. Mario Capecchi Drive, Salt Lake City, UT 84113, USA.
International journal of molecular sciences
|June 27, 2024
概括
细胞染色体P450 3A5 (CYP3A5) 酶的遗传变异对喘控制有影响. 特定的CYP3A5基因型与较差的喘结果有关,包括更多的恶化和住院治疗,这表明个性化治疗策略.
科学领域:
- 药物遗传学 药物遗传学
- 喘管理 喘管理
- 呼吸系统医学 呼吸系统医学
背景情况:
- 药物代谢酶的遗传变异可能会影响治疗疗效.
- 关于吸入性皮质类固醇 (ICS) 代谢酶遗传学对喘控制的影响的证据有限.
- 细胞染色体P450 3A5 (CYP3A5) 是药物代谢中的一个关键酶.
研究的目的:
- 调查CYP3A5基因中单核酸多态 (SNPs) 与儿童和青少年喘结果之间的关联.
- 评估CYP3A5基因型对喘控制,恶化和住院治疗的影响.
- 探索CYP3A5遗传学对皮质类固醇药理动力学和ICS剂后皮质醇水平的影响.
主要方法:
- 通过使用电子喘追踪器 (e-AT) 进行自我监测,招募751名患有持续性喘的儿童 (2-18岁).
- 在166名患者的小组中,从唾液样本中对CYP3A5SNP进行基因定型.
- 多变量回归分析,以评估CYP3A5基因型对喘控制,恶化和住院治疗的影响,调整为共变量.
- 在16名患者的ICS剂量后血皮质类固醇和皮质醇度的药理动力学 (PK) 分析.
主要成果:
- CYP3A5*1/*x基因型与每周喘控制的减少显著相关 (OR:0.98;p < 0.001).
- 患有CYP3A5*1/*x基因型的患者出现了喘恶化 (OR: 6.43; p < 0.001) 和住院治疗 (OR: 1.66; p < 0.001) 的增加.
- 基因基因分析表明,CYP3A5*3/*3基因型的皮质醇度发生了变化的变化,这表明对HPA轴的潜在影响,而不是直接的ICS代谢.
结论:
- CYP3A5遗传变异显著影响儿科患者的喘控制和结果.
- 这些发现支持了等位基因复制效应,其中不同的CYP3A5基因型对喘严重程度有不同的影响.
- 鉴定CYP3A5基因型可以在未来为喘提供个性化吸入类固醇治疗策略.
相关概念视频
Antiasthma Drugs: Leukotriene Modifiers
271
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
271
Antiasthma Drugs: Methylxanthines
215
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
215
Asthma-III: Symptoms and Complications
2.5K
Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma
Classification of Asthma
2.5K
Asthma-I: Introduction
2.6K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
120
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
120
Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K


